Laura Givens, MD
Family Medicine · San Antonio, TXNPI 1902957046
Payments from drug & device makers
Across 347 payments — averaging $69.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10K
- Otsuka America Pharmaceutical, Inc.$9K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$616
- Avanir Pharmaceuticals, Inc.$556
- Johnson & Johnson$427
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$14,84462%
- Travel & lodging$2,85112%
- Food & beverage$6,31526%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 42 | $10,281 |
| Otsuka America Pharmaceutical, Inc. | 37 | $8,932 |
| Teva Pharmaceuticals USA, Inc. | 107 | $1,532 |
| Neurocrine Biosciences, Inc. | 20 | $616 |
| Avanir Pharmaceuticals, Inc. | 30 | $556 |
| Johnson & Johnson | 29 | $427 |
| Urovant Sciences Inc | 19 | $323 |
| Alpha Cognition USA, Inc. | 5 | $278 |
| Lilly USA, LLC | 12 | $228 |
| Acadia Pharmaceuticals Inc | 6 | $177 |
| Sumitomo Pharma America, Inc. | 6 | $120 |
| AstraZeneca | 4 | $105 |
| Sunovion Pharmaceuticals Inc. | 6 | $94 |
| AbbVie(2 entities) | 5 | $78 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Indivior Inc. | 2 | $32 |
| Sun Pharmaceutical Industries Inc. | 2 | $30 |
| Nabriva Therapeutics, PLC | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Alkermes, Inc. | 1 | $22 |
| Abbott | 1 | $22 |
| MDD US Operations, LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Corium, LLC | 1 | $15 |
| Biogen | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,067 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 233 | $831,536 |
| IngrezzaValbenazine Tosylate | 155 | $675,227 |
| Invega SustennaPaliperidone Palmitate | 189 | $636,718 |
| EliquisApixaban | 1,760 | $509,826 |
| PerserisRisperidone | 119 | $349,246 |
| NuplazidPimavanserin Tartrate | 110 | $283,486 |
| GemtesaVibegron | 590 | $143,596 |
| Abilify MaintenaAripiprazole | 48 | $143,143 |
| XareltoRivaroxaban | 381 | $110,215 |
| MyrbetriqMirabegron | 438 | $107,677 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $96,600 |
| JardianceEmpagliflozin | 294 | $91,323 |
| TrulicityDulaglutide | 94 | $89,312 |
| RinvoqUpadacitinib | 11 | $80,436 |
| TradjentaLinagliptin | 302 | $79,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,532 | $831,536233 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta | $427 | $792,128602 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $616 | $675,227155 claims |
| Indivior Inc.Perseris | $32 | $349,246119 claims |
| Acadia Pharmaceuticals IncNuplazid | $177 | $283,486110 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $8,932 | $192,340115 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $120 | $143,596590 claims |
| AbbVieRinvoq, Linzess | $78 | $114,33967 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $107,677438 claims |
| Lilly USA, LLCTrulicity | $228 | $89,31294 claims |
| Alkermes, Inc.Aristada | $22 | $64,79120 claims |
| AstraZenecaFarxiga | $105 | $58,537189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Antonio
- Douglas DenhamSan Antonio$68.5M
- George AtieeSan Antonio$19.9M
- Leonel ReyesSan Antonio$4.3M
- Brian MacgillivraySan Antonio$3.2M
- Juan GarzaSan Antonio$2.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.